Hypercholesterolemia is a lipid disorder characterized by elevated cholesterol levels, especially LDL cholesterol, in the blood. Persistent elevation contributes to atherosclerosis and increased risk of coronary heart disease and stroke. It can be primary (genetic) or secondary to lifestyle and other medical factors.
LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.
mRNA medicine and spatiotemporal drug delivery systems are expanding options for cardiovascular disease. The sources describe preclinical proof-of-concept, clinical trials and programmable cardiac repair platforms.
Merck will present late-breaking clinical data from its cardio-pulmonary pipeline at ACC.26, including positive Phase 3 results for enlicitide, an investigational oral PCSK9 inhibitor, and Phase 2 data for WINREVAIR in heart failure patients.
The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.
The global CRISPR and prime editing market is forecast to grow at 24.1% CAGR through 2031, driven by therapeutic advances and regulatory progress. Scribe Therapeutics achieved a second milestone with Eli Lilly, while new RNA production and gene editing technologies accelerate research.
A 30-year-old female with stage IV gallbladder adenocarcinoma achieved complete metabolic resolution of metastases after three cycles of pembrolizumab, gemcitabine, and cisplatin, despite presenting without traditional risk factors.
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
The FDA approved multiple denosumab biosimilars in late 2025 and issued REMS safety updates emphasizing severe hypocalcemia risk in patients with advanced chronic kidney disease, including reported hospitalizations and fatalities.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07581808 |
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention |
NOT_YET_RECRUITING | PHASE4 |
| NCT07564726 |
Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol |
COMPLETED | PHASE3 |
| NCT07524101 |
Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD |
NOT_YET_RECRUITING | NA |
| NCT07514663 |
Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile |
RECRUITING | NA |
| NCT07508254 |
Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome |
NOT_YET_RECRUITING | PHASE4 |
| NCT07489183 |
A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older |
COMPLETED | |
| NCT07477704 |
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia |
NOT_YET_RECRUITING | PHASE2 |
| NCT07474649 |
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events |
NOT_YET_RECRUITING | PHASE3 |
| NCT07447206 |
Vascular Intervention Strategies Trial for Alzheimer's |
NOT_YET_RECRUITING | PHASE2 |
| NCT07445542 |
Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia |
COMPLETED |
